Dr. Lionel Kankeu Fonkoua: Helping at-risk patients and increasing diversity in clinical trials
By Deb Balzer
Meet Lionel Kankeu Fonkoua, M.D., an oncologist with the Mayo Clinic Comprehensive Cancer Center who specializes in the treatment of gastrointestinal cancers. He's also a Robert Winn Career Development Award recipient dedicated to helping minority and at-risk people through research and clinical trials.
Watch Dr. Kankeu Fonkoua discuss his research and his path to medicine in this video:
Dr. Kankeu Fonkoua is leading a clinical trial through the Robert A. Winn Diversity in Clinical Trials Award Program.
"It's a program that's designed to make sure that those clinical trials are community designed, conducted and informed to make sure that whatever research we do, we have the intent from the get-go of thinking about the communities that are at risk, vulnerable and most likely to benefit," says Dr. Kankeu Fonkoua.
His study focuses on the immigrant African and Asian communities of Minnesota with a high prevalence of hepatitis-induced hepatocellular carcinoma — a type of liver cancer.
"This is an at-risk population that we are intentionally targeting, because they are not represented in a lot of our immunotherapy trials," he explains.
And that can be a problem for the people who need treatment the most.
"It's very important to make sure that the at-risk population — the vulnerable population that's going to most likely benefit the most from the therapy — is represented. Because you have to tell them (and) it's hard to tell a patient this is a study, a clinical trial, that had 1,000 patients, (and) only 1% to 2% were actually like you," says Dr. Kankeu Fonkoua.
Representation and building trust matter when working with patients.
"It helps me (in) that initial contact, that initial trust. Someone might be more receptive if you know it's coming from someone with the same race, from the same ethnicity or, more importantly, from the same background and life experience."
Through the study, Dr. Kankeu Fonkoua hopes to help patients who are not eligible for surgery by combining radiation therapy with a dendritic cell vaccine —a type of immune cell modified in a laboratory and given after radiation therapy.
"That's a combination of radiation therapy with dendritic cell vaccine, that's innovation. That's an innovative type of approach to really use the patient's own cells that we modify — immune cells that we modify — to target their own tumor specific antigens. So those are therapies that five to 10 years ago or more, we didn't have the ability to do. And I think that's kind of where we are moving forward," Dr. Kankeu Fonkoua says.
What may be surprising is that Dr. Kankeu Fonkoua says he did not intend to be a doctor.
"I was supposed to be an engineer," he says.
It was his grandmother's battle with gastric cancer.
"There were not a lot of options, not a lot of meaningful treatment options, and not a lot of research going on," says Dr. Kankeu Fonkoua.
That steered him toward a new path.
"My parents definitely raised me with that scientific method — both scientists — but I think the drive to go into this humane profession, the spirit behind it, is my grandmother."
He says his grandmother's spirit inspires him still to this day.
"To be honest, in every patient, I see her and the opportunity to provide better care and, hopefully, outcomes than she had."
To hear more from Dr. Kankeu Founkoua, read these articles:
To learn more about the importance of increasing diversity in clinical trials, read these articles:
To learn more about liver cancer, read these articles:
- "Researchers hope to eliminate hepatitis, a common risk factor for liver cancer"
- "Treating and preventing liver cancer"
A version of this article was originally published on the Mayo Clinic News Network.
Mayo Clinic researchers are using AI to develop ways to find more colon polyps and detect pancreatic cancer at an earlier stage.
Dr. Lionel Kankeu Founkoua hopes for a future in which cancer research benefits all people with cancer, including those who are not currently represented in clinical trials.
The discovery strengthens evidence that the microbiome is an important indicator for early detection of ovarian cancer.